■在过去的二十年中,新型治疗靶标的识别导致多发性骨髓瘤(MM)药物获得批准的步伐无非是惊人的。然而,MM仍然是一种不治之症。因此,迫切需要额外的,创新疗法。免疫功能障碍和肿瘤允许的免疫骨髓微环境代表MM病理生理学的标志。针对SLAMF7和CD38的裸单克隆抗体已经构成了当今MM治疗的支柱。新型免疫治疗方式,包括抗体-药物缀合物(ADC),双特异性抗体(BsAb),和嵌合抗原受体T细胞正在再次彻底改变未来的MM疗法。
■本综述文章总结了在2021年美国血液学会年会上发表的关于MM免疫疗法的最新结果;并概述了正在进行的旨在进一步提高其疗效的临床前和临床努力。同时降低其毒性。
■在获得一流的BCMA靶向ADC(belantamabmafodotin)和两种BCMA靶向CART细胞产品(Ide-cel,Cilta-cel);以及即将批准的一流BCMaxCD3BsAb,MM中的现代下一代免疫疗法的时代正在不断发展。MM的长期无病生存和潜在治愈终于可以实现。
UNASSIGNED: The pace at which the identification of novel therapeutic targets has led to the approval of multiple myeloma (MM) agents during the last two decades is nothing more than spectacular. Nevertheless, MM remains an incurable disease. Therefore, there is an urgent need for additional, innovative therapeutics. Immune dysfunction and the tumor-permissive immune bone marrow microenvironment represent hallmarks of MM pathophysiology. Naked monoclonal antibodies directed against SLAMF7 and CD38 already constitute backbones of today\'s MM therapy. Novel immunotherapeutic modalities including antibody-drug-conjugates (ADC), bispecific antibodies (BsAb), and chimeric-antigen-receptor T cells are on the way to once more revolutionize future MM therapy.
UNASSIGNED: The present review article summarizes the most recent results on MM immunotherapies presented at the 2021 Annual Meeting of the American Society of Hematology; and throws a glance on ongoing preclinical and clinical efforts aiming at further increasing their efficacy, while reducing their toxicity.
UNASSIGNED: With the approvals of the first-in-class BCMA-targeting ADC (belantamab mafodotin) and two BCMA-targeting CAR T cell products (Ide-cel, Cilta-cel); and the approval of the first-in-class BCMAxCD3 BsAb immediately pending, the era of modern next-generation immunotherapies in MM is continuously evolving. Long-term disease-free survival and potential cure of MM are finally within reach.